Monte Rosa Therapeutics, Inc. GLUE
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is an immunology/inflammation drug developer. Its lead program, MRT-8102 (NEK7 molecular glue degrader), is in Phase 1 for Inflammatory diseases (NEK7/NLRP3-driven).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MRT-6160 (VAV1) - licensed to Novartis, Novartis-sponsored | Immune-mediated diseases | small molecule | Phase 2 |
| MRT-8102 (NEK7) | Inflammatory diseases | small molecule | Phase 1 |
| MRT-2359 (GSPT1) | Metastatic castration-resistant prostate cancer / MYC-driven tumors | small molecule | Phase 1 |
| CCNE1/CDK2 degrader | Oncology | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.